1. Volume 15, Issue 4, Pages 424-435 (April 2014)
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial 
Dr Kirit M Ardeshna, FRCP, Wendi Qian, PhD, Paul Smith, MSc, Nivette Braganca, MSc, Lisa Lowry, FRCPath, Pip Patrick, PhD, June Warden, MSc, Lindsey Stevens, Christopher F E Pocock, PhD, Fiona Miall, MD, Prof David Cunningham, FMedSci, John Davies, FRCP, Andrew Jack, FRCP, Richard Stephens, MA, Jan Walewski, MD, Prof Burhan Ferhanoglu, MD, Prof Ken Bradstock, PhD, Prof David C Linch, FMedSci 
The Lancet Oncology 
Volume 15, Issue 4, Pages (April 2014)
DOI: /S (14)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
On Sept 30, 2007, recruitment into the rituximab induction group was closed and the study was amended to a two-arm study. *Inclusive of the patients enrolled in the three-arm study (83 in the watch and wait group and 85 in the maintenance rituximab group).
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2 Kaplan-Meier curves for the two-arm study
(A) Time to start of new treatment, (B) progression-free survival, (C) overall survival, and (D) time to histological transformation. HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3
Kaplan-Meier curves for the 252 patients randomly assigned in the initial three-arm study
(A) Time to start of new treatment, (B) progression-free survival, (C) overall survival, and (D) time to histological transformation. HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions